I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 150, 7004

Edward J. Milbrada 40,090

Name of Agent Registration No.

Signature of Agent

Signature of Agent

MAD 1 8 2004

P&G Case 9469

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

•

Barry Feist

Confirmation No.

Serial No. 10/737,236

: Group Art Unit

Filed December 16, 2003

Examiner

For Child's Aromatherapy Cleaning Implement

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [X] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] <u>Information to be Considered with Continued Prosecution Application</u> (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for <u>Design Case</u>). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature. OR [] (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and						
37 C.F.R. §	1.98(a)(2),	Applicants are subm	itting copies of foreign patent documents and non-			
patent literat	ture.					
			OR			
[] (3)	All of the	cited references were	e previously cited by or submitted to the USPTO in			
prior applica	ation Case	No, U.S. Pate	nt Application Serial No, filed Applicants			
claim priori	ty to said	application under 35	5 U.S.C. §120. Accordingly, copies of previously			
submitted re	eferences ar	e not provided with	this Statement, pursuant to 37 C.F.R. §1.98(d). It is			
respectfully	requested	that the cited docum	nents be carefully considered by the Examiner and			
made of rec	ord in this o	case.				
			OR			
[] (4)	Copies of	all said documents,	except Cite Numbers, were submitted			
and conside	red in pare	ent application U.S.	Patent Application Serial No, filed			
·	Applicant(s) claim priority to sa	aid application under 35 U.S.C. §120. Accordingly,			
copies of pr	eviously su	ibmitted references a	re not provided with this Statement, pursuant to 37			
C.F.R. §1.98	8(d). Copi	es of references not p	previously submitted are enclosed. It is respectfully			
requested th	at the cited	documents be carefu	ally considered by the Examiner and made of record			
in this case.						
[] (5)	Pursuant t	o 37 C.F.R. §1.98(c),	a concise explanation of the relevance of each cited			
reference that	at is not in	the English language	is provided.			
[] (6)	Applicant	s also respectfully re	quest the Examiner to consider and make of record			
		tions listed on the atta				
the co-pend	ing applica	nons fisted on the att	ienea page.			
ſΊ	Additiona	l information is attacl	hed			
LJ	71001110110	i momunion io ucuo				
			Respectfully submitted,			
			By Edward O William			
Data: Ma	Edward J. Milbrada					
Customer	Agent for Applicant(s) Registration No. 40,090					
(IDS.doc) (Last			(513) 626-1167			

PTO/SB08A (08-03) U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to the 1995, no persons are required

INFORMATION DIS	SCLOSURE
STATEMENT BY A	PPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

SHEET

1 of 3

COMPL	ETE IF KNOWN
Application Number	10/737,236
Confirmation Number	
Filing Date	December 16, 2003
First Named Inventor	Barry Feist
Group Art Unit	
Examiner Name	
Attorney Docket Number	9469

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines Where Relevant Passages or Relevan
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Figures Appear
		US-2,798,053	07-02-1957	Brown	
		US-2,831,854	04-22-1958	Tucker et al.	
	<u> </u>	US-3,755,560	08-28-1973	Dickert et al.	
		US-3,862,472	01-28-1975	Norton et al.	
		US-3,929,678	12-30-1975	Laughlin et al.	
		US-3,963,669	06-15-1976	Rizzi et al.	
		US-3,967,756	07-06-1976	Barish	
		US-3,982,302	09-28-1976	Vaalburg	
		US-3,982,659	09-26-1976	Ross	
	<u> </u>	US-3,986,479	10-19-1976	Boedecker	
		US-3,994,417	11-30-1976	Boedecker	
		US-4,004,323	01-25-1977	Gotchel et al.	
		US-4,005,195	01-25-1977	Jandacek	
		US-4,005,196	01-25-1977	Jandacek	
		US-4,057,669	11-08-1977	McConnell	
		US-4,097,965	07-04-1978	Gotchel et al.	
		US-4,130,915	12-26-1978	Gotchel et al.	
		US-4,135,024	01-16-1979	Callahan et al.	
		US-4,176,427	12-04-1979	Neuenschwander	
		US-4,189,896	02-26-1980	Kolbach et al.	
		US-4,207,367	06-10-1980	Baker	
		US-4,296,161	10-20-1981	Kaiser et al.	
		US-4,309,469	01-05-1982	Varona	
		US-4,421,769	12-20-1983	Dixon et al.	
		US-4,471,881	09-18-1984	Foster	
		US-4,509,949	04-05-1985	Huang et al.	
		US-4,517,360	05-21-1985	Volpenhein	
		US-4,518,772	05-21-1985	Volpeinhein	
		US-4,599,379	07-08-1986	Flesher et al.	·
		US-4,628,078	12-09-1986	Glover et al.	
		US-4,637,859	01-20-1987	Trokhan	
		US-4,682,942	07-28-1987	Gotchel et al.	
		US-4,741,855	05-03-1988	Grote et al.	
		US-4,797,300	01-10-1989	Jandacek et al.	<u> </u>
		US-4,835,206	05-30-1989	Farrar et al.	
		US-4,840,270	06-20-1989	Caputo	
		US-4,849,484	07-18-1989	Heard	
		US-4,960,764	10-02-1990	Figueroa, Jr. et al.	
		US-4,971,220	11-20-1990	Kaufman	
		US-4,976,953	12-11-1990	Orr et al.	
		US-5,050,737	09-24-1991	Josylin	
		US-5,087,445	02-11-1992	Haffey et al.	
		US-5,100,600	03-31-1992	Hawe et al.	
		US-5,223,096	06-29-1993	Phan et al.	
		US-5,240,562	08-31-1993	Phan et al.	
		US-5,305,514	04-26-1994	Letton et al.	
		US-5,305,514 US-5,305,516	04-26-1994	Letton et al.	
		US-5,305,516 US-5,306,515	04-26-1994	Letton et al.	

	US-5,322,178	06-21-1994	Foos	
	US-5,366,104	11-22-1994	Armstrong	
	US-5,487,884	01-30-1996	Bissett et al.	
	US-5,556,509	09-17-1996	Trokhan et al.	
	US-5,580,423	12-03-1996	Ampulski et al.	
	US-5,607,980	03-04-1997	McAtee et al.	
	US-5,647,506	07-15-1997	Julius	
	US-5,686,082	11-01-1997	N'Guyen	
	US-5,785,179	07-28-1998	Buczwinski	
	US-5,791,465	08-11-1998	Niki	
	US-5,883,998	11-10-1998	Biederman et al.	
	US-5,939,082	08-17-1999	Oblong et al.	
-	US-6,092,690	07-25-2000	Bitowft	
	US-6,200,554	03-13-2001	Yeoh et al.	
	US-6,248,317	06-19-2001	Snyder et al.	
	US-6,269,969	08-07-2001	Huang	
	US-6,269,970	08-07-2001	Huang	
	US-6,280,751	08-28-2001	Fletcher et al.	
	US-6,296,144	10-02-2001	Tanaka	-
	US-6,315,114	11-13-2001	Keck	
•	US-6,335,312	01-01-2002	Coffindaffer et al.	
	US-6,401,968	06-11-2002	Huang	
	US-6,412,634	07-02-2002	Telesca	
	US-6,440,347	08-27-2002	Krzysik et al.	
	US-6,506,394	01-14-2003	Yohiaoui et al.	
	US-6,630,175	10-07-2003	Shapiro et al.	
	US-D414,637	10-05-1999	Amundson	
	US-D416,794	11-23-1999	Cormack	
	US-D421,901	03-28-2000	Hill	
	US-D421,902	03-28-2000	Hill	
	US-D437,686	02-20-2001	Balzar	
	US-D443,451	06-12-2001	Buck	
	US-D443,508	06-12-2001	Braaten	
	US-D445,329	07-24-2001	Zethoff	
	US-D451,279	12-04-2001	Chin	
	US-2002/0064323	05-30-2002	Chin	
	US-2002/0177535 A1	11-28-2002	Piterski et al.	
	US-2003/0130636 A1	07-10-2003	Brock et al.	
	US-2003/0190337 A1	10-09-2003	Bissett	
	US-2003/0217425	11-27-2003	Datta et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T⁵
		EP 0 228 868 A2		07-15-1987	Allied Colloids Limited		
		WO 97/39733 A1		10-30-1997	The Procter & Gamble Co.		
		WO 99/55213 A1		11/14/99	The Procter & Gamble Co.		
		WO 00/27268 A1		05-18-2000	The Procter & Gamble Co.		
		WO 02/14172 A1		02-21-2002	The Procter & Gamble Co.		
		WO 04/018746 A1		03-04-2004	Kimberly-Clark Worldwide, Inc.		
EXAMINER	}				DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

The optional is unique citation designation number (optional).

See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

The optional is unique citation designation number (optional).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.